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Abstract
Background The incidence and age distribution of membranoproliferative glomerulonephritis (MPGN) vary throughout the 
world by race and ethnicity. We sought to evaluate the clinical features, pathogenesis, and age distribution of MPGN among 
a large nationwide data from the Japan Renal Biopsy Registry (J-RBR).
Methods A cross-sectional survey of 593 patients with MPGN (types I and III) registered in the J-RBR between 2007 and 
2015 was conducted. Clinical parameters, and laboratory findings at diagnosis were compared between children (< 20 years), 
adults (20–64 years), and elderly patients (≥ 65 years).
Results The median age of the patients was 59.0 years and mean proteinuria was 3.7 g/day. The rate of nephrotic syndrome 
was significantly higher in adults (40.4%) and elderly patients (54.0%) than in children (14.9%), whereas the rate of chronic 
glomerulonephritis was significantly higher in children (66.2%) than in adults (34.4%) and elderly patients (31.2%). Accord-
ing to the CGA risk classification, high-risk (red zone) cases accounted for 3.4% of children, 52.5% of adults and 84.1% 
of elderly patients with MPGN. As for pathogenesis, primary MPGN was most frequent (56.0%). Lupus nephritis was the 
most common disease among adult patients with secondary MPGN, whereas infectious disease was more common in elderly 
patients. Multiple regression analysis revealed that high systolic blood pressure and high proteinuria were independent factors 
associated with decreased estimated glomerular filtration rate (eGFR) in adults and elderly patients with MPGN.
Conclusions In Japan, adults and elderly patients with MPGN had a lower eGFR and severer proteinuria than children.
Keywords Membranoproliferative glomerulonephritis · Renal pathology · Registry · Age distribution
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Introduction
Membranoproliferative glomerulonephritis (MPGN), also 
termed as mesangiocapillary glomerulonephritis, is a mor-
phological pattern of injury characterized by mesangial 
hypercellularity, endocapillary proliferation, capillary 
wall remodeling, double contour formation, and duplica-
tion of basement membranes on light microscopy [1, 2]. 
In the clinical setting, MPGN is one of the most com-
mon causes of nephrotic syndrome in both children and 
adults, and accounts for approximately 2–10% of all cases 
of biopsy-confirmed glomerulonephritis [3–6]. Tradition-
ally, MPGN has been classified based on the findings of 
electron microscopy as primary MPGN type I (MPGN I), 
MPGN II, MPGN III, or secondary MPGN [1, 2]. MPGN 
I, the most common form, is characterized by subendothe-
lial deposits, and MPGN III has both subepithelial and 
subendothelial deposits, whereas MPGN type II is char-
acterized by dense deposits in the glomerular basement 
membrane (dense deposit disease [DDD]) [1, 2]. Together 
with DDD, this group of C3-positive immunoglobulin-
negative glomerular diseases has been labeled as C3 glo-
merulopathies [7, 8]. Furthermore, the MPGN has the 
strongest association with secondary causes, including 
viruses, autoimmune diseases, and paraproteins [1, 9]. 
However, the clinical features and pathogenesis of MPGN 
in an adequate sample of patients at different ages have not 
been studied in detail. We, therefore, surveyed the clinical 
features and pathogenesis of MPGN types I and III based 
on data between July 2007 and June 2015 from the Japan 
Renal Biopsy Registry (J-RBR), which is a nationwide, 
web-based, prospective registry of renal biopsies.
Methods
Registry description
The J-RBR was established by the Committee for the 
Standardization of Renal Pathological Diagnosis and the 
Working Group for the Renal Biopsy Database of the Jap-
anese Society of Nephrology in 2007 [10]. Patient data 
were registered on the J-RBR website using the Inter-
net Data and Information Center for Medical Research 
(INDICE) system of the University Hospital Medical 
Information System (UMIN). The J-RBR is registered 
under the Clinical Trial Registry of UMIN (Registra-
tion Number, UMIN000000618), and the Ethics Review 
Board of the Japanese Society of Nephrology approved the 
present study in accordance with the Declaration of Hel-
sinki. Written informed consent was obtained from all the 
patients at the time they were registered to participate in 
the study. Among the 26,535 patients with biopsy-proven 
disease who were registered in this system between July 
2007 and June 2015, we selected 593 (2.2%) patients with 
MPGN who were registered as having a histopathology 
of MPGN types I and III. The patients were classified as 
children, adults, and elderly according to age < 20 years, 
20–64 years, and ≥ 65 years, respectively.
Clinical diagnoses and parameters
According to the modified classification of World Health 
Organization, primary glomerular diseases were mainly 
clinically diagnosed as chronic nephritic syndrome, acute 
nephritic syndrome, recurrent or persistent hematuria, rap-
idly progressive nephritic syndrome, and nephrotic syn-
drome [10]. Secondary glomerular diseases were categorized 
as renal disorders with collagen disease or vasculitis, renal 
disease with metabolic syndrome, hypertensive nephropathy, 
acute kidney injury, drug-induced nephropathy, thrombotic 
microangiopathy, and others. The J-RBR requires classifi-
cation based on pathogenesis and histopathology. All the 
extracted patients were registered as having a histopathology 
of MPGN type I and III. Patients with DDD were excluded 
from this study.
Evaluation of other clinical findings
The registered basic information (age, sex, height, and 
weight) as well as urinary findings (urinalysis, daily pro-
teinuria), blood findings (serum creatinine, total protein, 
serum albumin, total cholesterol), blood pressure (BP) and 
the presence of concomitant hypertension and diabetes were 
assessed in the present study. Estimated glomerular filtration 
rate (eGFR) was calculated using the modified equations for 
Japanese children [11] and for Japanese adults [12]. Informa-
tion about prescribed anti-hypertensive agents, the presence 
of diabetes mellitus, and HbA1c were arbitrarily registered. 
We analyzed the frequency of high-risk (red zone) cases 
of primary MPGN according to patient age, based on the 
CGA risk classification for CKD (the heat map method), as 
described previously [13].
Statistical analysis
Continuous variables, except age, are presented as 
mean ± standard deviation. Age is expressed as median 
and interquartile range. Clinical parameters were compared 
among the three patient age groups using a single-factor 
analysis of variance for normally distributed continuous var-
iables or the Kruskal–Wallis test for non-normally distrib-
uted continuous variables. The normality of the variances 
for each continuous variable was analyzed using Levene 
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test. Differences in proportions were evaluated using the Chi 
square independent test or Fisher’s exact test, depending on 
the number of categories. Independent factors affecting renal 
function at diagnosis were evaluated using stepwise multi-
ple regression analyses. Quantitative variables such as body 
mass index calculated by height and weight, proteinuria, sys-
tolic BP, serum albumin, and serum total cholesterol were 
selected as independent variables in the analyses. Age, sex, 
and the value of serum creatinine were excluded, because 
these variables were used in the equation of eGFR. All data 
were statistically analyzed using IBM SPSS Advanced Sta-
tistical Version 19.0 (SPSS, Chicago, IL, USA), and p < 0.05 
was considered to indicate a significant difference.
Results
General data of patients
Patient demographics of MPGN in Japan are shown in 
Table 1 and Fig. 1. Among the 593 patients with MPGN, 
319 (53.8%) were male and 274 (46.2%) were female. The 
median age of the overall patients was 59.0 years (61.0 years 
for men and 56.0 years for women). The number of regis-
tered patients increased with age and peaked in the seventh 
decade for the overall patients and male patients, whereas 
it peaked in the eighth decade for female patients (Fig. 1a).
The urinary findings of the patients are shown in Table 2. 
In dipstick tests, 36 cases (6.1%) were classified as (−) or 
(±), and 377 cases (63.6%) were classified as ≥ 3+. Simi-
larly, 28 cases (6.5%) and 18 cases (4.1%) involved patients 
who exhibited daily proteinuria values of < 0.3 g/day or 
urinary protein/creatinine ratios (UPCR) of < 0.3 g/gCr 
(spot urine tests). In addition, 385 cases (89.8%) and 412 
cases (92.8%) involved patients who demonstrated daily 
proteinuria values of ≥ 0.5 g/day and UPCR of ≥ 0.5 g/gCr, 
respectively.
In this study, the mean daily proteinuria was 3.7 g, mean 
UPCR was 4.8 g/gCr, mean serum albumin level was 2.9 g/
dL, and mean eGFR was 57.8 mL/min/1.73 m2 (Table 1). 
When we judged the nephrotic state of the patients based on 
the new criteria for nephrotic syndrome used in Japan [14]; 
i.e., daily proteinuria (or a UPCR) of more than 3.5 g (or g/
gCr) and serum albumin levels less than 3.0 g/dL or serum 
total protein levels less than 6.0 g/dL, 297 (253 patients 
with nephrotic syndrome and 44 patients with nephrotic 
syndrome with collagen disease/vasculitis)(50.1%) of the 
593 patients with MPGN were considered to be nephrotic 
(Fig. 1c; Table 3). The frequency of nephrotic state increased 
with age, from 10% in the first decade to 70% in the ninth 
decade (Fig. 1c).
With regard to hematuria, 123 cases (20.8%) were found 
to be (−) or (±) for occult blood in dipstick tests, and 386 
cases (65.1%) were classified as ≥ 2+. Similarly, 156 cases 
(26.3%) were considered to be red blood cell (RBC)-neg-
ative or to have < 5 RBC/high-powered field (hpf) in their 
urinary sediments, and 169 cases (28.5%) and 170 cases 
(28.7%) were considered to have < 10–30/hpf and many/hpf, 
respectively (Table 2).
Clinical features and pathogenesis of MPGN
The main clinical diagnoses of the overall patients with 
MPGN at the time of renal biopsy were nephrotic syndrome 
in 253 patients (42.7%), chronic nephritic syndrome in 220 
patients (37.1%), nephrotic syndrome with collagen disease/
vasculitis in 44 patients (7.4%), and chronic nephritic syn-
drome with collagen disease/vasculitis in 34 patients (5.7%) 
(Table 3).
In the present analysis, 332 (56.0%) of the 593 patients 
were registered as ‘‘primary’’ MPGN, whereas 261 patients 
(44.0%) were registered as ‘‘secondary’’ MPGN (Table 3), 
including 74 (12.5%) patients with lupus nephritis, 72 
patients (12.1%) with infectious disease (hepatitis B virus: 
5, hepatitis C virus: 38, and shunt infection: 3), and 29 
patients (4.9%) with IgA nephropathy (Fig. 1b; Table 3). In 
the remarks columns of the database, there were 32 patients 
(5.2%) with cryoglobulinemia, 5 patients with light-chain 
deposition disease, 3 patients with heavy-chain deposition 
disease, and 2 patients with C3 glomerulopathies. As for the 
Table 1  Patient demographics of membranoproliferative glomerulo-
nephritis in Japan (J-RBR 2007–2015)
J-RBR Japan Renal Biopsy Registry, eGFR estimated glomerular fil-
tration rate, HbA1c hemoglobin A1c
N Min Max Mean SD
Age (years old) 593 3 89 52.7 22.4
Male 319 3 89 54.1 21.2
Female 274 4 88 51.0 23.6
Height (cm) 582 94.5 186.1 157.8 12.7
Weight (kg) 581 15.2 107.6 57.0 13.8
Body mass index (BMI) 581 10.4 37.6 22.6 3.8
Proteinuria (g/day) 429 0.0 19.4 3.7 3.2
Urinary protein/creatinine ratio 444 0.0 32.0 4.8 4.2
Serum creatinine (mg/dl) 593 0.2 9.7 1.3 1.0
eGFR (mL/min/1.73 m2) 588 6.4 161.3 57.8 32.1
Serum total protein (g/dl) 592 3.3 9.9 5.8 1.0
Serum albumin (g/dl) 592 1.1 5.0 2.9 0.8
Serum total cholesterol (mg/dl) 575 78.0 558.0 225.4 72.8
Systolic blood pressure (mmHg) 507 87.0 227.0 138.1 21.5
Diastolic blood pressure (mmHg) 507 38.0 114.0 77.4 13.3
Mean blood pressure (mmHg) 507 57.0 146.3 97.6 14.2
HbA1c (%) 366 3.8 14.2 5.7 0.8
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age distribution of the MPGN patients, more than 80% of the 
patients in their first and second decade were registered as 
primary MPGN, whereas around 60% of the patients in their 
fourth and fifth decade were registered as secondary MPGN 
(Fig. 1b). Lupus nephritis was the most common disease 
among patients with secondary MPGN in their third and 
fourth decade, whereas infectious disease was more common 
in the fifth decade and beyond (Fig. 1b).
Around 70% of patients aged less than 20 years and 
more than 90% of patients aged more than 20 years had 
severe proteinuria (A3)(Fig. 1d). The number of patients 
with advanced chronic kidney disease (CKD)(stage G3a to 
G5) increased with age, and more than 70% of the patients 
were 60 years old or older (Fig. 1e). According to the CGA 
risk classification, high-risk (red zone) cases accounted 
for 3.4% of children, 52.5% of adults and 84.1% of elderly 
Fig. 1  Age distribution and clinical features of membranoprolif-
erative glomerulonephritis (MPGN) in the J-RBR. a The number 
of cases peaked in the seventh decade for the overall patients and 
male patients, whereas they peaked in the eighth decade for female 
patients. b The number of pathogenesis of MPGN. The number 
of cases with primary MPGN, lupus nephritis, and infectious dis-
ease peaked in the eighth, fourth, and seventh decade, respectively. 
Lupus nephritis was the most common disease among patients with 
secondary MPGN in their third and fourth decade, whereas infec-
tious disease was the most common in their fifth decade and beyond. 
c The number of nephrotic syndrome in patients with MPGN, and 
age distribution of the population. The frequency of nephrotic state 
increased with age. d–e chronic kidney disease (CKD) A stages (d) 
and G stages (e) of MPGN. More than 90% of patients aged 20 years 
and above had severe proteinuria (A3) (d). The number of patients 
with advanced CKD (stage G3a, G3b, G4, or G5) increased with age, 
and more than 70% of them were 60 years old or older (e). f–h The 
CGA risk classification of MPGN. According to the CGA risk clas-
sification, high-risk (red zone) cases accounted for 3.4% of patients 
aged under 20 years (f), 52.5% of patients aged 20 to 64 years (g) and 
84.1% of those aged over 65 years (h)
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patients with MPGN (Fig. 1f–h), suggesting that compared 
to children, adults and elderly patients with MPGN have 
more severe renal involvement according to advanced age.
Table 4 compares the clinical features between chil-
dren, adults, and elderly patients with MPGN. The rate 
of nephrotic syndrome was significantly higher in adults 
(40.4%) and elderly patients (54.0%) than in children 
(14.9%), whereas the rate of chronic glomerulonephri-
tis was significantly higher in children (66.2%) than in 
adults (34.4%) and elderly patients (31.2%). The number 
of patients with hypertension, large amount of proteinuria, 
reduced renal function, and hypoalbuminemia distinctly 
differed among the age groups, and disease severity was 
worse in elderly patients with MPGN. In contrast, the ratio 
of overt hematuria (> 30/hpf) (40.5 vs. 24.5 vs. 29.5%) was 
worse in children with MPGN (Table 4), suggesting that 
children are more likely to have hematuria at onset and 
less likely to have renal insufficiency and hypertension, 
as previously reported [15].
Clinical features of primary MPGN
Next, we focused on only primary MPGN. Of the 26,535 
total renal biopsies, 332 patients were registered as primary 
MPGN (1.3%). Among these, 185 patients (55.7%) were 
male and 147 (44.3%) were female. The median age of the 
patients was 61.0 years. The number of patients increased 
with age and peaked in the eighth decade for the overall 
patients and female patients, whereas it peaked in the sev-
enth decade for male patients (Fig. 2a). The mean proteinu-
ria was 3.8 g/day, mean serum albumin was 3.0 g/dL, and 
mean eGFR was 59.0 mL/min/1.73 m2 (Table 5).
The main clinical diagnoses of the patients with primary 
MPGN were nephrotic syndrome in 163 patients (49.1%) 
and chronic nephritic syndrome in 148 patients (44.6%). The 
diagnosis of nephrotic syndrome was found to increase with 
age, whereas that of chronic nephritic syndrome decreased 
with age in patients with primary MPGN. Around 70% 
of patients aged less than 20 years and more than 90% of 
patients aged more than 20 years had severe proteinuria 
(A3) (Fig. 2b). The number of patients with advanced CKD 
(stage G3a to G5) increased with age, and more than 80% of 
Table 2  Urinalysis results of all cases of membranoproliferative glomerulonephritis in Japan (J-RBR 2007–2015)
J-RBR Japan Renal Biopsy Registry, OB occult blood levels according to the dipstick test, hpf high powered field
Urinary protein (dipstick test) Cases %
(−) 16 2.7
(±) 20 3.4
1+ 48 8.1
2+ 132 22.3
3+ 258 43.5
4+ 119 20.1
Total 593 100.0
Daily proteinuria levels and urinary protein levels according to spot urine tests
g/day Cases % g/g Cr Cases %
< 0.3 28 6.5 < 0.3 18 4.1
0.3–0.49 16 3.7 0.3–0.49 14 3.2
0.50–0.99 44 10.3 0.50–0.99 30 6.8
1.0–3.49 149 34.7 1.0-3.49 159 35.8
3.5+ 192 44.8 3.5+ 223 50.2
Total 429 100.0 Total 444 100.0
Hematuria (occult blood grade and red blood cell grade of urinary sediment)
OB Cases % /hpf Cases %
(−) 58 9.8 (−) 26 4.4
(±) 65 11.0 < 5 130 21.9
1+ 84 14.2 5–10 98 16.5
2+ 169 28.5 < 10–30 169 28.5
3+ 217 36.6 Many 170 28.7
Total 593 100 Total 593 100.0
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these patients were 60 years old or older (Fig. 2c). Accord-
ing to the CGA risk classification, high-risk (red zone) cases 
accounted for 4.0% of children, 53.9% of adults and 84.7% 
of elderly patients with primary MPGN (Fig. 2d–f) as simi-
lar to overall MPGN.
The ratios of nephrotic syndrome (16.7 vs. 48.8 vs. 
62.9%) were significantly higher, whereas those of chronic 
nephritic syndrome (76.7 vs. 46.5 vs. 29.4%) were sig-
nificantly lower in elderly patients than in adults and chil-
dren (Table 6). The disease severity was worse in elderly 
patients with primary MPGN as similar to overall MPGN.
Impact of clinical features on renal function
As for hypertension, BP and/or the intake of anti-hyper-
tensive drugs were registered in 520 patients with MPGN. 
Hypertension, as judged by a systolic BP of more than 
140 mmHg, a diastolic BP of more than 90 mmHg, or drug 
intake, was observed in 374 (71.9%) patients with MPGN.
The impact of clinical factors on renal function at the 
time of biopsy was evaluated using multiple regression 
analysis. The model included important risk factors for 
progression of renal function as imperative independent 
variables. Higher systolic BP and serum total cholesterol, 
and increased proteinuria at diagnosis were significant 
factors for a decline in renal function in adult and elderly 
patients with overall MPGN (R2 = 0.104; F = 13.021, 
p < 0.001; Table 7a) and with primary MPGN (R2 = 0.157; 
F = 10.791, p < 0.001; Table 7b).
Discussion
This is the first study to characterize the clinical features 
using the CGA risk classification and pathogenesis of 
MPGN in a large nationwide registry of renal biopsies. 
Table 3  Clinical diagnoses 
and pathogenesis of 
membranoproliferative 
glomerulonephritis in Japan 
(J-RBR 2007–2015)
J-RBR Japan Renal Biopsy Registry, HUS/TTP hemolytic uremic syndrome/thrombotic thrombocytopenic 
purpura, MPO-ANCA myeloperoxidaseantineutrophil cytoplasmic antibody
Cases %
Clinical diagnoses
 Nephrotic syndrome 253 42.7
 Chronic nephritic syndrome 220 37.1
 Nephrotic syndrome + collagen disease/vasculitis 44 7.4
 Chronic nephritic syndrome + collagen disease/vasculitis 34 5.7
 Rapidly progressive nephritic syndrome 19 3.2
 Acute nephritic syndrome 12 2.0
 Recurrent hematuria 5 0.8
 HUS/TTP 2 0.3
 Acute kidney injury 2 0.3
 Acute nephritic syndrome + collagen disease/vasculitis 1 0.2
 Rapidly progressive nephritic syndrome + collagen disease/vasculitis 1 0.2
 Total 593 100
Pathogenesis
 Primary (idiopathic) 332 56.0
 Lupus nephritis 74 12.5
 Infection-related nephropathy 72 12.1
 IgA nephropathy 29 4.9
 Thrombotic microangiopathy 8 1.3
 Purpura nephritis 7 1.2
 Diabetic nephropathy 6 1.0
 Amyloidosis 4 0.7
 Hypertensive nephrosclerosis 3 0.5
 MPO-ANCA-positive nephritis 2 0.3
 Transplanted kidney 2 0.3
 Others 54 9.1
 Total 593 100
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MPGN commonly presents in childhood, but can be 
observed at all ages. Adult and elderly patients with 
MPGN had a higher frequency of nephrotic syndrome, 
clinical hypertension, heavy proteinuria, and hypoalbu-
minemia at the time of biopsy than that observed in chil-
dren with MPGN.
The incidence of MPGN has been reported to decrease 
over time from about 7–10% in the 1970s to about 2% dur-
ing 1990–2011 [3–6, 16–19]. In the present study, among 
the 26,535 patients with biopsy-confirmed disease, 593 
(2.2%) patients were registered as having a histopathology 
of MPGN types I and III. Further, 332 out of the 26,535 
Table 4  Comparison of clinical features and pathogenesis according to age in patients with membranoproliferative glomerulonephritis
eGFR estimated glomerular filtration rate, hpf high powered field, RPGN rapidly progressive nephritic syndrome, HUS/TTP hemolytic uremic 
syndrome/thrombotic thrombocytopenic purpura, MPO-ANCA myeloperoxidaseantineutrophil cytoplasmic antibody
Child Adult Elderly P
N 74 282 237
Age (years old) 11.9 ± 4.1 46.0 ± 13.3 73.4 ± 5.7 < 0.001*
Male/female 36/38 158/124 125/112 0.483
Body mass index (BMI) 18.8 ± 3.1 23.2 ± 3.6 23.1 ± 3.6 < 0.001*
Systolic blood pressure (mmHg) 113.0 ± 15.0 135.6 ± 18.7 147.8 ± 19.8 < 0.001*
Diastolic blood pressure (mmHg) 64.7 ± 10.8 80.0 ± 12.9 77.6 ± 12.4 < 0.001*
Patients with hypertension at diagnosis 17.3% 60.5% 86.4% < 0.001*
Sediment RBC (> 30/hpf, %) 40.5% 24.5% 29.5% 0.027*
Proteinuria (g/day) 1.7 ± 2.1 3.8 ± 3.0 3.9 ± 3.5 < 0.001*
Urinary protein/creatinine ratio 2.6 ± 3.9 4.5 ± 3.6 5.7 ± 4.8 < 0.001*
Serum creatinine (mg/dl) 0.71 ± 1.11 1.22 ± 0.75 1.56 ± 1.08 < 0.001*
eGFR (mL/min/1.73 m2) 106.2 ± 28.9 60.4 ± 28.4 40.3 ± 18.7 < 0.001*
Serum albumin (g/dl) 3.4 ± 0.9 2.9 ± 0.8 2.7 ± 0.7 < 0.001*
Serum total cholesterol (mg/dl) 216.9 ± 74.4 229.5 ± 77.5 223.2 ± 66.2 0.354
Clinical diagnosis
 Nephrotic syndrome 11 (14.9%) 114 (40.4%) 128 (54.0%) < 0.001*
 Chronic nephritic syndrome 49 (66.2%) 97 (34.4%) 74 (31.2%) < 0.001*
 Nephrotic syndrome + collagen disease/vasculitis 3 (4.1%) 30 (10.6%) 11 (4.6%) 0.017*
 Chronic nephritic syndrome + collagen disease/vasculitis 6 (8.1%) 25 (8.9%) 3 (1.3%) 0.001*
 RPGN 1 (1.4%) 7 (2.5%) 11 (4.6%) 0.238
 Acute nephritic syndrome 1 (1.4%) 5 (1.8%) 6 (2.5%) 0.753
 Recurrent hematuria 2 (2.7%) 2 (0.7%) 1 (0.4%) 0.163
 HUS/TTP 1 (1.4%) 0 (0.0%) 1 (0.4%) 0.195
 Acute kidney injury 0 (0.0%) 1 (0.4%) 1 (0.4%) 0.859
 Acute nephritic syndrome + collagen disease/vasculitis 0 (0.0%) 0 (0.0%) 1 (0.4%) 0.471
 RPGN + collagen disease/vasculitis 1 (1.4%) 7 (2.5%) 11 (4.6%) 0.238
Pathological diagnosis
 Primary (idiopathic) 60 (81.1%) 129 (45.7%) 143 (60.3%) < 0.001*
 Lupus nephritis 8 (10.8%) 52 (18.4%) 14 (5.9%) < 0.001*
 Infection-related nephropathy 0 (0.0%) 37 (13.1%) 35 (14.8%) 0.002*
 IgA nephropathy 3 (4.1%) 20 (7.1%) 6 (2.5%) 0.053
 Thrombotic microangiopathy 1 (0.0%) 6 (1.8%) 3 (1.3%) 0.495
 Purpura nephritis 2 (2.7%) 3 (1.1%) 2 (0.8%) 0.420
 Diabetic nephropathy 0 (0.0%) 1 (0.4%) 5 (2.1%) 0.090
 Amyloidosis 0 (0.0%) 2 (0.7%) 2 (0.8%) 0.737
 Hypertensive nephrosclerosis 0 (0.0%) 0 (0.0%) 3 (1.3%) 0.104
 MPO-ANCA-positive nephritis 0 (0.0%) 1 (0.4%) 1 (0.4%) 0.859
 Transplanted kidney 0 (0.0%) 2 (0.7%) 0 (0.0%) 0.331
 Others 0 (0.0%) 29 (10.3%) 23 (9.7%) 0.017*
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(1.3%) patients were registered as primary MPGN. In a 
comprehensive epidemiological study, the lesion of MPGN 
was observed in about 2% of patients with biopsy-confirmed 
glomerulonephritis in the Australia [3] and United States 
[19]. As for primary MPGN, a recent report from Japan has 
showed a 1.2% incidence of primary MPGN in a total of 
6,369 renal biopsies [17]. The present study confirmed these 
findings.
MPGN is the sixth leading cause of end-stage renal dis-
ease among the glomerulonephritides and the fifth leading 
cause of end-stage renal disease among the primary glo-
merular diseases, as reported in an international comparative 
study including patients in the United States, Europe, and 
Australia/New Zealand [16]. In the present study, accord-
ing to the CGA risk classification, high-risk (red zone) 
cases accounted only for 3.4% of children with MPGN, 
whereas these cases accounted for 52.5 and 84.1% of adult 
and elderly patients with overall MPGN, respectively. Simi-
larly, these cases accounted for 4.0% of children, 53.9% of 
adults and 84.7% of elderly patients with primary MPGN. 
These results suggest that MPGN is an important disorder 
leading to end-stage renal disease, even in Japan. Further, 
higher value for systolic BP and serum total cholesterol, and 
Fig. 2  Age distribution and clinical features of primary membrano-
proliferative glomerulonephritis (MPGN). a The number of cases 
peaked in the seventh decade for male patients, whereas they peaked 
in the eighth decade for the overall patients and female patients. b–c 
Chronic kidney disease (CKD) A stages (b) and G stages (c) of pri-
mary MPGN. More than 90% of patients aged more than 20 years had 
severe proteinuria (A3) (b). The number of patients with advanced 
CKD (stage G3a, G3b, G4, or G5) increased with age, and more than 
70% of them were 60 years old or older (c). d–f The CGA risk classi-
fication of primary MPGN. According to the CGA risk classification, 
high-risk (red zone) cases accounted for 4.0% of patients aged under 
20 years (d), 53.9% of patients aged 20 to 64 years (e) and 84.7% of 
those aged over 65 years (f)
Table 5  Patient demographics of primary MPGN in Japan (J-RBR 
2007–2015)
J-RBR Japan Renal Biopsy Registry, eGFR estimated glomerular fil-
tration rate, HbA1c hemoglobin A1c
N Min Max Mean SD
Age (years old) 332 3 89 51.6 24.6
Male 185 3 89 53.5 23.1
Female 147 4 87 49.2 26.4
Height (cm) 328 94.5 183.0 156.3 14.3
Weight (kg) 327 15.2 102.6 55.3 14.0
Body mass index (BMI) 327 10.4 34.9 22.3 3.8
Proteinuria (g/day) 232 0.0 19.4 3.8 3.4
Urinary protein/creatinine ratio 250 0.0 32.0 5.0 4.6
Serum creatinine (mg/dl) 332 0.2 9.7 1.3 1.1
eGFR (ml/min/1.73 m2) 328 6.4 161.3 59.0 33.8
Serum total protein (g/dl) 332 3.3 8.7 5.7 1.0
Serum albumin (g/dl) 331 1.1 5.0 3.0 0.8
Serum total cholesterol (mg/dl) 324 78.0 558.0 230.7 73.3
Systolic blood pressure (mmHg) 284 87.0 197.0 137.9 22.4
Diastolic blood pressure (mmHg) 284 42.0 114.0 76.1 13.4
Mean blood pressure (mmHg) 284 57.0 135.0 96.7 14.5
HbA1c (%) 192 3.8 7.4 5.6 0.5
805Clinical and Experimental Nephrology (2018) 22:797–807 
1 3
increased proteinuria at diagnosis were significant factors 
for a decline in renal function in adult and elderly patients 
not only with overall MPGN but also with primary MPGN, 
suggesting that management of BP might be important 
for retarding the decline of renal function in patients with 
MPGN.
The reason why the older patients had more proteinuria 
and worse renal function might be that the older patients 
had MPGN for a long time or late stage, although we have 
no data about the duration between disease onset and renal 
biopsy. Moreover, the present data including glomerulo-
nephritides with established disease entities such as lupus 
nephritis, IgA nephropathy, and MPO-ANCA-positive 
nephritis might be difficult to interpret legitimately to evalu-
ate the clinical features of MPGN, because these diseases 
generally show different clinical features and develop in dif-
ferent age groups.
Primary MPGN is a diagnosis of exclusion, at least in 
many adults and some children, and a systematic approach 
to evaluation will often uncover a secondary cause, such as 
an infection, autoimmune disease, monoclonal gammopathy, 
neoplasia, complement dysregulation, or a chronic throm-
botic microangiopathy [1, 9]. Several studies have indicated 
that secondary MPGN is most often due to hepatitis C and 
other infections [1, 9]. Although the prevalence and age dis-
tribution of secondary MPGN had remained uncertain, we 
clearly showed that lupus nephritis was the most common 
disease among patients with secondary MPGN patients aged 
20–39 years, whereas infectious disease was the most com-
mon among patients aged 40 years and above.
This study has some limitations. First, we cannot exclude 
the possibility that the J-RBR is subject to sampling bias; 
however, the registry contributes to not only the stand-
ardization of histological diagnosis and classification, but 
also to nationwide epidemiological studies of conditions 
such as nephrotic syndrome and glomerulonephritis [6, 
Table 6  Comparison of clinical 
features and diagnosis among 
age group in primary MPGN
eGFR estimated glomerular filtration rate, hpf high powered field
Child Adult Elderly P
N 60 129 143
Age (years old) 11.4 ± 4.2 45.8 ± 13.7 73.6 ± 5.6 < 0.001*
Male/Female 27/33 79/50 79/64 0.111
Body mass index (BMI) 18.9 ± 3.3 22.8 ± 3.2 23.3 ± 3.7 < 0.001*
Systolic blood pressure (mmHg) 112.8 ± 15.8 136.0 ± 18.1 148.2 ± 20.3 < 0.001*
Diastolic blood pressure (mmHg) 64.4 ± 11.5 79.3 ± 12.5 77.3 ± 12.8 < 0.001*
Patients with hypertension at diagnosis 13.3% 51.2% 67.8% < 0.001*
Sediment RBC (> 30/hpf, %) 38.3% 23.3% 32.2% 0.078
Proteinuria (g/day) 1.8 ± 2.2 4.0 ± 3.2 4.2 ± 3.6 0.003*
Urinary protein/creatinine ratio 2.6 ± 4.2 4.5 ± 3.4 6.2 ± 5.2 < 0.001*
Serum creatinine (mg/dl) 0.75 ± 1.23 1.29 ± 0.85 1.56 ± 1.06 < 0.001*
eGFR (ml/min/1.73 m2) 104.2 ± 30.5 59.6 ± 28.7 40.2 ± 18.6 < 0.001*
Serum albumin (g/dl) 3.5 ± 0.9 3.0 ± 0.8 2.8 ± 0.7 < 0.001*
Serum total cholesterol (mg/dl) 219.1 ± 73.4 237.9 ± 76.1 229.3 ± 70.3 0.251
Clinical diagnosis
 Nephrotic syndrome 10 (16.7%) 63 (48.8%) 90 (62.9%) < 0.001*
 Chronic nephritic syndrome 46 (76.7%) 60 (46.5%) 42 (29.4%) < 0.001*
 Rapidly progressive nephritic syndrome 1 (1.7%) 3 (2.3%) 6 (4.2%) 0.531
 Acute nephritic syndrome 0 (0.0%) 1 (0.8%) 1 (0.7%) 0.798
 Recurrent hematuria 2 (3.3%) 1 (0.8%) 0 (0.0%) 0.163
 Acute kidney injury 0 (0.0%) 1 (0.8%) 1 (0.7%) 0.798
Table 7  Impact of clinical features and pathogenesis on renal func-
tion at the time of biopsy in adult and elderly patients with mem-
branoproliferative glomerulonephritis (MPGN)
*Statistically significant by multiple regression analysis (stepwise 
method)
Parameters at diagnosis Standard b t P
(a) MPGN
 Systolic blood pressure − 0.248 − 4.740 < 0.001
 Proteinuria (g/day) − 0.177 − 3.255 0.001
 Serum total cholesterol 0.108 1.998 0.046
R2 = 0.104; F = 13.021, p < 0.001*
(b) Primary MPGN
 Systolic blood pressure − 0.299 − 4.254 < 0.001
 Proteinuria (g/day) − 0.216 − 2.957 0.004
 Serum total cholesterol 0.147 2.030 0.044
R2 = 0.157; F = 10.791, p < 0.001*
806 Clinical and Experimental Nephrology (2018) 22:797–807
1 3
20–22]. Thus, it is likely to be reasonably representative of 
the nationwide situation of renal biopsied cases in Japan. 
Second, the registry data might be somewhat inaccurate. 
Although it is necessary to exclude the secondary cause of 
MPGN before confirming a diagnosis of primary MPGN, 
we cannot exclude the possibility that some patients who 
were registered as primary MPGN had underlying infectious 
diseases, autoimmune diseases, or paraproteins at the time 
of registration. Third, the number of items on the registra-
tion form was so definitive that we were unable to evaluate 
the immunological data; for example, complements, anti-
nuclear antibody, and immunofluorescence findings of the 
renal biopsies, although the diagnosis of MPGN has recently 
changed from an electron microscopy-based ultrastructural 
classification scheme to one based largely on immunofluo-
rescence findings [1, 23, 24]. Finally, this cross-sectional 
study had no reference to the duration between disease onset 
and renal biopsy, the treatments and outcomes of any of the 
patients. However, the baseline data of this study have a 
potential to be helpful in further studies such as a longitudi-
nal cohort study. From this perspective, a large longitudinal 
cohort study should be planned to clarify and compare the 
actual outcomes in MPGN and C3 glomerulopathy.
In conclusion, the frequency of patients who were reg-
istered as MPGN peaked between the ages of 60 and 79 
years, and adults and elderly patients with MPGN had a 
lower eGFR and severer proteinuria than children, in the 
Japanese nationwide registry. The clinical characteristics 
and actual renal outcomes of patients with MPGN and C3 
glomerulopathy require further longitudinal investigation.
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